scientific reports

Check for updates

OPEN Risk factors for poor outcome in childhood tuberculous meningitis

Mao-Shui Wang^{1,2}, Mei Zhao³ & Xin-Jie Liu¹

Tuberculous meningitis (TBM) remains a serious disease for children and its risk factors of poor outcome remain unclear. Therefore, a retrospective study was conducted aiming to investigate the risk factors associated with poor outcome of childhood TBM. Between January 2006 and December 2019, consecutive children patients (< 15 years old) who had a diagnosis of TBM were included for the analysis. The demographic, clinical, laboratory, and radiographic data were collected from the electronic medical records retrospectively. Poor outcome was defined as death or transfer to a higherlevel hospital. Patients were then divided into good and poor outcome groups. Subsequently, risk factors for poor outcome were estimated using univariate and multivariate logistic regression analysis. A total of 149 children with TBM was enrolled, twenty-two patients suffered poor outcome, including 16 transfers to a higher-level hospital and 6 deaths, and the remaining 127 patients were classified as good outcome group. Further multivariate analysis revealed that coma (age- and sex-adjusted OR = 6.425, 95% CI: 1.743, 23.676; P < 0.01) and cerebrospinal fluid (CSF) protein (> 1188.3 mg/L; ageand sex-adjusted OR = 4.680, 95% CI: 1.469, 14.902; P < 0.01) were associated with the poor outcome of childhood TBM. Childhood TBM remains to have a high mortality rate in China. High CSF protein and coma were identified as risk factors for poor outcome of childhood TBM. Hence, more attention is required to be paid to suspected patients with such characteristics, thus facilitating access to optimum treatment.

Currently, the situation of tuberculosis (TB) control in children has undergone many changes. First, the leading infectious agents causing death in children have shifted from rabies virus and M.tuberculosis to human immunodeficiency virus¹. Second, during the past years, the annual notified incidence of childhood pulmonary TB was low (compared with that of adults) and decreased significantly². However, TB caused by M.tuberculosis infection remains the most common bacterial infection in children and a serious public health threaten in China.

Tuberculous meningitis (TBM) is the most severe form of TB, leading to a high rate of mortality. In children, mortality rates of 15-29% were reported for TBM³⁻⁵. Recently, our findings demonstrated that the proportion of TBM among childhood TB in Shandong, China, is estimated at 9.4%, a remarkably high value required for effective intervention⁶. In addition, during the last decade, the trend in the proportion of TBM among childhood TB suggested a steady-state⁶. Therefore, a better management of childhood TBM is required to improve the current situation of TB patients, especially the survival rate.

It is well-known that delays in initiating therapy for TBM would increase mortality⁷. Unfortunately, the diagnosis of TBM in children is difficult. For example, routine microbiological examinations (such as smear and culture) show limited capacity in the diagnosis of the disease among children; polymerase chain reaction (PCR) has a moderate sensitivity in the diagnosis⁸, and a similar result was reported, when cerebrospinal fluid (CSF) Xpert was applied⁹; metagenomic next-generation sequencing is also tested in the diagnosis of TBM and presented with a moderate diagnostic performance¹⁰. The diagnosis remains a clinical challenge and this would contribute a significant delay in the initiation of anti-TB therapy, which may lead to a poor outcome. Hence, to characterize the risk factors associated with the poor outcome may improve the present situation in the management of childhood TBM.

The current study aims to investigate the risk factors for a poor outcome of TBM in children. There are few studies that address the factors associated with the outcome of TBM in this population. Our findings may be helpful in understanding the clinical characteristics of children patients with poor outcomes, and may improve the management of the disease.

¹Department of Pediatrics, Qilu Hospital, Cheeloo College of Medicine, Shandong University, 107#, Wenhuaxi Road, Jinan 250012, Shandong, China. ²Department of Lab Medicine, Shandong Provincial Chest Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China. ³Department of Pediatrics, Shandong Maternal and Child Health Hospital, Jinan, Shandong, China. email: liuxinjie@sdu.edu.cn

Materials and methods

The study was approved by the Ethics Committee of Shandong Provincial Chest Hospital, Jinan, China (NO. 2020XKYYEC-29) and performed in compliance with Helsinki declaration. Due to the retrospective nature of the study design and anonymous data collection, written informed consent was waived by the Ethics Committee of Shandong Provincial Chest Hospital.

Between January 2006 and December 2019, consecutive children patients (\leq 15 years old) who had a diagnosis of TBM were included for the analysis. TBM was defined if one of the following criteria (modified from the criteria established by Marais et al.¹¹) was met: (1) definite: acid fast bacilli (AFB, +) on cerebrospinal fluid (CSF) microscopy, or CSF TB-PCR(+), or *M.tuberculosis* cultured from CSF. (2) conclusive: symptoms and signs of meningitis and CSF findings (such as total white cell count > 5 cells × 10⁶/L, protein > 0.45 g/L, glucose < 2.2 mmol/L, and CSF/serum glucose ratio < 0.5), *plus* at least one of the following (i) TB suggested by abnormal radiographic features (chest, or cerebral imaging), (ii) positive TB assays (such as AFB, PCR, and culture) using non-CSF samples. All patients were censored at death or discharge from our center.

The demographic, clinical, laboratory, and radiographic data were collected from the electronic medical records retrospectively. Poor outcome was defined as death or transfer to a higher-level hospital. Then, patients were divided into good and poor outcome groups and analyzed. Subsequently, risk factors for poor outcome were estimated in the study.

Statistical analysis were performed using SPSS version 16.0 (SPSS, Chicago, IL, USA). Continuous variables were expressed as mean \pm standard deviation (SD) and categorical variables as count (percentages). Univariate and multivariate logistic regression analysis adjusted by age and sex were performed to determine risk factors for poor outcomes, and odds ratios (OR) and the corresponding 95% confidence interval (CI) were calculated¹². Additionally, to make a better clinical understanding, continuous variables were transformed into categorical variables, based on cutoffs determined by the receiver operating characteristic curve (ROC) analysis. The goodness-of-fit was assessed using the Hosmer–Lemeshow test. A *P* value < 0.05 was considered significant.

Results

Patient characteristics. A total of 149 children was enrolled during the study period. Twenty-two patients suffered poor outcomes, including 16 transfers to a higher-level hospital and 6 deaths. Table 1 shows a comparison of clinical-pathological characteristics between patients with poor and good outcomes.

In general, 22 patients were grouped as poor outcome group, and the remaining 127 patients as good outcome group. The mean age and weight were 7.8 ± 5.3 years and 24.2 ± 16.0 kg, respectively. Of them, eighty-two patients (55.0%) were male and 120 (80.5%) were from rural areas. Additionally, other sites involved with TB were reported as pulmonary (45.0%), miliary (15.4%), lymph node (4.0%), and pleural (4.0%). Among them, 30 patients (good outcome group, n = 25; poor outcome group, n = 5) have been confirmed with TBM: CSF culture (+, n = 24); CSF AFB (+, n = 2); TB PCR (+, n = 13); CSF Xpert (+, n = 2).

The mean times of hospitalization were 2.1 ± 1.7 , and the mean treatment delay was reported at 40 ± 61 days. Among the enrolled patients, 32 patients (21.5%) had a TB contact history and 128 patients (85.9%) were transferred from a teaching hospital. Almost all patients (96.0%) had inpatient therapy, over half (58.4%) had outpatient therapy, and a significant proportion (13.4%) were reported having self-treatment. In addition, a majority (76.5%) of patients had experienced antibiotics therapy and a few (20.8%) were administrated with anti-TB therapy.

The vital signs were as follows: temperature, 37.3 ± 0.9 °C; heart rate, 99.2 ± 21.5 beats/min; respiratory rate, 22.6 ± 3.0 breaths/min; systolic pressure, 106.9 ± 16.1 mmHg; diastolic pressure, 68.9 ± 11.5 mmHg. The symptoms were as follows: fever (88.6%), headache (51.7%), vomiting (48.3%), cough (20.1%), convulsion (16.8%), coma (14.8%), drowsiness (9.4%), and dizziness (3.4%). In addition, a total of 16 patients (10.7%) were reported with symptoms related to cranial nerve involvement: motor abnormalities (n=7), speech difficulty (n=4), swallowing difficulty (n=1), and visual loss (n=4).

T-SPOT.TB were tested in 38 patients and 26 (68.4%) of them had a positive result. Other lab examinations, such as blood cell count, flow cytometry, and CSF analysis, were shown in Table 1 and Supplementary Table 1.

Univariate and multivariate analysis. Table 1 shows the results of univariate analysis between poor and good outcome groups. It was found that poor outcome was associated with systolic pressure (OR = 1.025, 95% CI: 1.002, 1.048), frequency of hospitalization (OR = 0.437, 95% CI: 0.207, 0.924), self-treatment (OR = 3.027, 95% CI: 1.017, 9.005), CSF protein (OR = 1.001, 95% CI: 1.000, 1.001), CSF α -hydroxybutyrate dehydrogenase (α -HBDH, OR = 1.007, 95% CI:1.000, 1.014), and CSF IgA (OR = 1.043, 95% CI: 1.001, 1.085; all *P* < 0.05).

Further multivariate analysis (Hosmer–Lemeshow goodness-of-fit test: χ^2 = 8.034, df = 8, *P* = 0.430) revealed that coma (age- and sex-adjusted OR = 6.425, 95% CI: 1.743, 23.676; *P* < 0.01) and CSF protein (>1188.3 mg/L; age- and sex-adjusted OR = 4.680, 95% CI: 1.469, 14.902; *P* < 0.01) were associated with the poor outcome of childhood TBM (Table 2).

Discussion

To our knowledge, this study is the first assessing the risk factors associated with poor outcome in childhood TBM in China. Our findings were based on a moderate sample size and suggested that an increased level of CSF protein and coma were associated with the poor outcome in children with TBM. TBM treatment is more difficult and prone to failure than pulmonary TB. Our data may be useful to improve the current situation of childhood TBM.

Delays in treatment have limited influence on the outcome of the disease. As reported previously, delay in the treatment of TBM was associated with a poor outcome¹³. Besides, similar findings were also found by Verdon et al.¹⁴, and Sheu et al.¹⁵. However, these findings disagreed with our findings, our data demonstrated that no

Demographic characteristics7.8 ± 5.36.9 ± 5.58.0 ± 5.20.3570.608See (male)82 (55.0%)11 (50.0%)71 (55.9%)0.6080.608Vital sigs37.3 ± 0.937.3 ± 0.937.3 ± 0.937.3 ± 0.90.6011.000Benyrature (°C)37.3 ± 0.237.3 ± 0.27.8 ± 0.90.8700.6011.000Respiratory rate (breats/min)22.6 ± 3.023.2 ± 3.425.5 ± 2.90.8180.0010.001Benyrature (°C)0.071106.9 ± 1.61114.4 ± 1.51105.4 ± 1.50.0780.078Disolatols pressure (mmHg)0.60 ± 1.120.0780.0780.0780.078Disolatols pressure (mmHg)32.0 (1.3%)6 (27.3%)10.0 (0.66%)0.4750.027 (1.017.9026)Disolatols pressure (mmHg)21.0 (1.3%)6 (27.3%)14.0 (1.0%6%)0.4370.027 (1.017.9026)Disolatols pressure (marking)21.1 (1.3%)(27.2%)14.0 (1.0%6%)0.4370.027 (1.017.9026)Disolation ressure (day (day))40.4 6143.4 440.4 640.8070.027 (1.017.9026)Distribution (day)40.1 (1.3%%)13.0 (1.3%)0.9420.027 (1.017.9026)Displation Listory143.96(0%)21.0 (5.5%)12.2 (6.1 %)0.943Distribution (day)40.2 (1.6 (5.5%)12.0 (6.1 %)0.027 (1.017.9026)Displation Listory143.0 (9.0 %)3 (13.6 %)3 (2.0 %)0.722Distribution (day)50.0 (1.5%)12.0 (6.1 %)0.1240.114Di		Total (n)	Poor group (n)	Good group (n)		
Age (years) 7.8 ± 5.3 6.9 ± 5.5 8.0 ± 5.2 0.357 Kex (male) 82 (55.0%) 11 (50.0%) 71 (55.9%) 0.608 Viral signs 37.3 ± 0.9 37.3 ± 0.9 37.3 ± 0.9 0.601 Iteart rate (beats/min) 92.2 ± 1.5 103.6 ± 29.7 98.5 ± 19.9 0.787 Respiratory rate (breath/min) 22.6 ± 3.0 23.2 ± 3.4 22.5 ± 2.9 0.818 Synolic pressure (mmHg) 106.9 ± 1.6.1 114.4 ± 1.51 105.4 ± 1.5.9 0.031 1.025 (1.002, 1.048) Obtacts history T 32.2 (1.5%) 6 (27.3%) 26 (20.5%) 0.475 Transferred from a teaching hospital 128 (85.9%) 18 (81.8%) 110 (86.6%) 0.552 Frequency of hospitalization 2.1 ± 1.7 1.2 ± 0.7 2.2 ± 1.8 0.030 0.437 (0.207, 0.924) Transferred (day) 40 ± 61 43 ± 43 40 ± 64 0.807 Data bistory 487 (68.4%) 13 (59.1%) 7 (58.3%) 0.427 Inarib matint history 13 (20.8%)	N	149	22	127	P value	OR (95% CI)
sex (male) 82 (55.0%) 11 (50.0%) 71 (55.9%) 0.608 Vital sigs	Demographic characteristics					
Vital signs Framerature (*C) 37.3 ± 0.9 37.4 ± 0.9 37.3 ± 0.9 6.001 Heart rate (beats/min) 99.2 ± 21.5 103.6 ± 29.7 98.5 ± 19.9 0.767 Sepiratory rate (breats/min) 99.2 ± 21.5 103.6 ± 29.7 98.5 ± 19.9 0.818 Systolic pressure (mmHg) 106.9 ± 16.1 114.4 ± 15.1 105.4 ± 15.9 0.011 1.025 (1.002, 1.048) Diastolic pressure (mmHg) 68.9 ± 11.2 73.3 ± 12.8 68.0 ± 11.2 0.078 Contact history of TB 32 (21.5%) 6 (27.3%) 26 (20.5%) 0.475 Frequency of hospitalization 21.1 ± 7 1.2 2.07 2.2 ± 1.8 0.030 0.437 (0.207, 0.924) Frequency of hospitalization 21.1 ± 7 1.2 (0.7 3%) 14 (1.0%) 0.46 3.027 (1.017, 9.005) Durt-patient history 143 (96.0%) 21 (93.5%) 122 (96.1%) 0.302 Intablicits therapy 114 (76.5%) 19 (86.4%) 9 (74.8%) 0.437 Symptoms 22 (1.45%) 3 (13.6%) 27 (21.3%	Age (years)	7.8±5.3	6.9 ± 5.5	8.0 ± 5.2	0.357	
Remperature (°C) 37,3 ± 0.9 37,4 ± 0.9 37,3 ± 0.9 0.601 Heart rate (beats/min) 22,6 ± 3.0 23,2 ± 3.4 22,5 ± 2.9 0.818 Respiratory rate (breath/min) 22,6 ± 3.0 23,2 ± 3.4 22,5 ± 2.9 0.818 Systolic pressure (mmHg) 66.9 ± 1.15 73,3 ± 1.28 66.0 ± 1.12 0.0781 Diatotic pressure (mmHg) 66.9 ± 1.15 73,3 ± 1.28 66.0 ± 1.12 0.0781 Contact history of TB 32 (21.5%) 6 (27.3%) 26 (20.5%) 0.475 Frequency of hospitalization 2,1 ± 1.7 1.2 ± 0.7 2,2 ± 1.8 0.000 0.437 (0.27, 0.924) Treatment delay (days) 40 ± 61 43 ± 43 40 ± 64 0.807 100.925 Directment delay (days) 40 ± 61 13 (59.1%) 74 (53.8%) 0.427 100.925 Sief-treatment 20 (13.4%) 6 (17.3%) 14 (11.0%) 0.447 100.925 Inpatient history 413 (96.0%) 13 (59.1%) 74 (53.8%) 0.427 100.925 Anti: B therapy 31 (20.8%) 13 (59.1%	Sex (male)	82 (55.0%)	11 (50.0%)	71 (55.9%)	0.608	
Hear rate (beats/min)99.2 ± 21.5103.6 ± 29.798.5 ± 19.90.787Respiratory rate (breats/min)22.6 ± 3.023.2 ± 3.422.5 ± 2.90.818Systolic pressure (mmHg)68.9 ± 11.573.3 ± 12.868.0 ± 11.20.078Distolic pressure (mmHg)68.9 ± 11.573.3 ± 12.868.0 ± 11.20.078Transferred from a teaching hospital128 (85.9%)18 (81.8%)110 (86.6%)0.552Frequency of hospitalization2.1 ± 1.71.2 ± 0.72.2 ± 1.80.3010.471 (0.207, 0.924)Frequency of hospitalization2.1 ± 1.71.2 ± 0.72.2 ± 1.80.3020.471 (0.207, 0.924)Frequency of hospitalization2.1 ± 1.71.2 ± 0.72.2 ± 1.80.3030.421 (0.207, 0.924)Frequency of hospitalization2.1 ± 1.71.2 ± 0.72.2 ± 1.80.3030.207 (1.017, 9.005)Out-patient history141 (76.5%)13 (59.1%)74 (58.3%)0.3420.327Frequency of hospitalization30 (0.1%)3 (13.6%)24 (2.0%)0.3720.372Symptoms51.3 (8.9.6%)0.4151.4 (0.207, 0.2240.272Congh30 (0.21%)3 (13.6%)26 (2.5%)0.2770.212Symptoms1.3 (8.9.6%)1.3 (8.9.6%)0.7220.271Frequency1.3 (8.8.6%)1.3 (8.9.6%)0.7220.271Congh30 (2.1%)5 (2.5%)6 (2.5%)0.277Frequency1.2 (4.8.%)1.3 (8.9.6%)0.722Congh1.4 (1.6%)1.	Vital signs					1
Respiratory rate (breaths/min)22.6 ± 3.023.2 ± 3.422.5 ± 2.90.8181025 (1.002, 1.048)Systolic pressure (mmHg)0.6 9 ± 1.6.111.4 ± 15.110.5 ± 1.5.90.0311.025 (1.002, 1.048)Diastolic pressure (mmHg)6.9 ± 1.6.173.3 ± 1.2.868.0 ± 1.1.90.0311.025 (1.002, 1.048)Diastolic pressure (mmHg)32 (21.5%)6 (27.3%)26 (20.5%)0.4750.475Frequency of hospitalization2.1 ± 1.71.2 ± 0.72.2 ± 1.80.3030.437 (0.207, 0.924)Frequency of hospitalization2.0 (3.4%)6 (27.3%)14 (1.0%)0.4643.027 (1.017, 9.005)Out-patient history14 (36.0%)2.1 (25.5%)1.2 (2.6 1.5%)0.3240.217 (1.017, 9.005)Out-patient history14 (36.0%)2.1 (25.5%)1.2 (2.6 1.5%)0.3750.121 (1.017, 9.005)Anti-TB trapy3 (3.0%)2.1 (2.16,5%)0.2470.121 (1.017, 9.005)Anti-TB trapy3 (3.0%)2.1 (2.16,5%)0.2470.121 (1.017, 9.012)Anti-TB trapy3 (3.0%)2.1 (2.16,5%)0.2750.121 (1.017, 9.012)Symptoms1.1 (4.75%)1.9 (6.4%)1.3 (8.0%)0.2720.121 (1.017, 9.012)Cordy2.0 (2.1%)3 (3.0%)2.7 (2.1.5%)0.2720.121 (1.017, 9.012)Cordy3 (3.0%)2.7 (2.1.5%)0.141 (1.017, 9.012)0.121 (1.017, 9.012)Cordy3 (3.0%)2.7 (2.1.5%)0.141 (1.017, 9.012)0.121 (1.017, 9.012)Cordy5 (3.6%)1.1 (4.05%)1.3 (0.9.6%	Temperature (°C)	37.3±0.9	37.4±0.9	37.3±0.9	0.601	
systolic pressure (nmHg)106.9 ± 16.1114.4 ± 15.1105.4 ± 15.90.0311.025 (1.002, 1.048)Diatobi pressure (nmHg)68.9 ± 11.57.3 ± 12.868.0 ± 11.20.0787.3 ± 12.868.0 ± 11.20.078Medical history52 (21.5%)6 (27.3%)26 (20.5%)0.4757.57.5Dransferred from a teaching hospital128 (85.9%)18 (81.8%)110 (86.6%)0.5527.5Frequency of hospitalization2.1 ± 1.71.2 ± 0.72.2 ± 1.80.0300.437 (0.207, 0.294)Treatment delay (days)40 ± 6143 ± 4340 ± 640.8077.5Caller teartment20 (13.4%)6 (27.3%)14 (11.0%)0.0463.027 (1.017, 9.005)Dat-patient history143 (96.0%)21 (95.5%)12 2 (96.1%)0.8433.0Antibotics therapy14 (76.5%)19 (96.4%)95 (74.8%)0.4277.6Symptoms30 (20.1%)3 (13.0%)26 (20.5%)0.2777.6Congh30 (20.1%)3 (13.0%)26 (25.5%)0.2777.6Prever12 (88.6%)13 (89.0%)13 (89.0%)0.2727.6Congh20 (21.5%)13 (90.0%)68 (53.5%)0.2777.6Conada21 (14.8%)8 (36.4%)14 (11.0%)0.0414.612 (451.45.2)Convalsion5 (3.4%)1 (4.5%)13 (13.0%)0.2797.6Convalsion5 (3.4%)1 (4.5%)13 (13.1%)0.7397.6Convalsion5 (3.4%)1 (4.5%)13 (1	Heart rate (beats/min)	99.2±21.5	103.6±29.7	98.5±19.9	0.787	
Distolic pressure (mm/Hg) 68.9 ± 11.5 73.3 ± 12.8 68.0 ± 11.2 0.078 Medical history Contact history of TB 32 (21.5%) 6 (27.3%) 26 (20.5%) 0.475 Fransferred from a teaching hospital 128 (85.9%) 18 (81.8%) 110 (86.6%) 0.552 Frequency of hospitalization 2.1 ± 1.7 1.2 ± 0.7 2.2 ± 1.8 0.300 0.437 (0.207, 0.924) Teatment delay (days) 40 ± 61 43 ± 43 40 ± 64 0.807 0.924 Durp atter history 10 ± 67 (58.4%) 13 (59.1%) 74 (58.3%) 0.942 0.927 Multiotis therapy 114 (76.5%) 19 (86.4%) 95 (74.8%) 0.247 0.417 Anti-TB therapy 31 (20.8%) 31 (36.9%) 27 (21.3%) 0.415 0.927 Symptoms 13 (59.1%) 59 (66.5%) 0.277 0.001 Consid 30 (20.1%) 31 (36.9%) 13 (10.9%) 0.727 0.001 Conside 13 (59.1%) 59 (66.5%) 0	Respiratory rate (breaths/min)	22.6±3.0	23.2±3.4	22.5±2.9	0.818	
Medical history Second Se	Systolic pressure (mmHg)	106.9±16.1	114.4±15.1	105.4±15.9	0.031	1.025 (1.002, 1.048)
Contact history of TB 32 (21.5%) 6 (27.3%) 26 (20.5%) 0.475 Frequency of hospitalization 2.1 ± 1.7 1.2 (85.9%) 18 (81.8%) 110 (86.6%) 0.552 Frequency of hospitalization 2.1 ± 1.7 1.2 ± 0.7 2.2 ± 1.8 0.030 0.437 (0.207, 0.2	Diastolic pressure (mmHg)	68.9±11.5	73.3±12.8	68.0±11.2	0.078	
Transferred from a teaching hospital128 (85.9%)18 (81.8%)110 (86.6%)0.5520Frequency of hospitalization2.1 ± 1.71.2 ± 0.72.2 ± 1.80.0300.437 (0.207, 0.204)Treatment delay (days)40 ± 6143 ± 4340 ± 640.8070Cell Freatment20 (13.4%)6 (27.3%)14 (11.0%)0.0463.027 (1.017, 9.005)Dut-patient history143 (96.0%)12 (95.5%)122 (96.1%)0.8330Antibotis therapy114 (76.5%)19 (86.4%)95 (74.8%)0.2470Antibotis therapy31 (20.1%)3 (13.6%)27 (21.3%)0.4150Symptoms50 (20.1%)13 (59.1%)59 (46.5%)0.2770Cough30 (20.1%)13 (59.1%)59 (46.5%)0.2770Cough72 (14.3%)13 (59.1%)59 (46.5%)0.2770Coma22 (14.8%)8 (36.4%)14 (11.0%)0.0044.612(1.645, 12.932)Drowsiness14 (9.4%)1 (4.5%)13 (10.2%)0.4120Convulsion25 (16.8%)5 (22.7%)20 (15.7%)0.412Drozziness5 (3.4%)1 (4.1%)1.0140Symptoms related to cranial nerve involvement*16 (42.5%)13 (10.2%)0.412Creebroppint Huid analysis71.8± 10.9%1.02.9%0.412Drozziness15 (6.2%)7.8± 10.9%1.0140.114Credit (10%)76 ± 257.6± 247.6± 250.648Polyonuclear cell (%)76 ±	Medical history		1	1		1
Frequency of hospitalization 2.1 ± 1.7 1.2 ± 0.7 2.2 ± 1.8 0.030 0.437 (0.207, 0.924) Ireatment delay (days) 40 ± 61 43 ± 43 40 ± 64 0.807 Self-treatment 20 (13.4%) 6 (27.3%) 14 (11.0%) 0.046 3.027 (1.017, 9.005) Dut-patient history 87 (58.4%) 13 (59.1%) 74 (68.3%) 0.942 Anti-Th therapy 114 (76.5%) 19 (86.4%) 95 (74.8%) 0.247 Anti-Th therapy 31 (20.8%) 3 (13.6%) 28 (22.0%) 0.375 Symptoms	Contact history of TB	32 (21.5%)	6 (27.3%)	26 (20.5%)	0.475	
Treatment delay (days) 40 ± 61 43 ± 43 40 ± 64 0.807 Self-treatment $20 (13.4\%)$ $6 (27.3\%)$ $14 (11.0\%)$ 0.046 $3.027 (1.017, 9.005)$ Dut-patient history $87 (58.4\%)$ $12 (55.1\%)$ $74 (58.3\%)$ 0.942 Impatient history $143 (06.0\%)$ $21 (95.5\%)$ $122 (96.1\%)$ 0.893 Antibiotics therapy $114 (76.5\%)$ $19 (86.4\%)$ $95 (74.8\%)$ 0.427 Anti-TB therapy $31 (20.8\%)$ $3 (13.6\%)$ $28 (22.0\%)$ 0.375 Symptoms 27 $27 (21.3\%)$ 0.415 $27 (21.3\%)$ 0.415 Cough $30 (20.1\%)$ $3 (13.6\%)$ $29 (46.5\%)$ 0.722 $27 (21.3\%)$ Vanitting $72 (48.3\%)$ $13 (59.1\%)$ $59 (46.5\%)$ 0.277 Headache $77 (51.7\%)$ $9 (40.9\%)$ $68 (53.5\%)$ 0.277 Coma $22 (14.8\%)$ $8 (36.4\%)$ $113 (80.0\%)$ 0.412 Convulsion $25 (16.8\%)$ $5 (22.7\%)$ 0.412 $20 (15.7\%)$ Convulsion $25 (16.8\%)$ $5 (22.7\%)$ 0.142 $20 (15.7\%)$ Orwaines $5 (3.4\%)$ $1 (4.5\%)$ $12 (9.4\%)$ 0.720 Creterospinal fluid analysis $16 (10.7\%)$ $4 (18.2\%)$ 0.142 Mice bold cell (10^{4}) $155.2 + 283.5$ $71.8 \pm 10.9.4$ 170.9 ± 301.8 0.14 Mononuclar cell ($\%)$ 25 ± 2.5 25 ± 2.4 24 ± 2.5 0.947 Catard thermoloxin framese (U/L) 55 ± 10.8 42 ± 1.97 0.235 Idal pr	Transferred from a teaching hospital	128 (85.9%)	18 (81.8%)	110 (86.6%)	0.552	
Self-treatment 20 (13.4%) 6 (27.3%) 14 (11.0%) 0.046 3.027 (1.017, 9.005) Dut-patient history 87 (58.4%) 13 (59.1%) 74 (58.3%) 0.942 Inpatient history 143 (96.0%) 21 (95.5%) 122 (96.1%) 0.893 Antibiotics therapy 114 (76.5%) 19 (86.4%) 95 (74.8%) 0.247 Anti-TB therapy 31 (20.8%) 3 (13.6%) 27 (21.3%) 0.415 Symptoms 132 (88.6%) 19 (86.4%) 113 (89.0%) 0.277 Cough 30 (20.1%) 3 (13.6%) 27 (21.3%) 0.415 Fever 132 (88.6%) 19 (86.4%) 113 (89.0%) 0.277 Comating 72 (14.8%) 13 (59.1%) 59 (46.5%) 0.277 Comation 22 (14.8%) 8 (36.4%) 14 (1.0%) 0.041 Convusion 25 (16.8%) 5 (22.7%) 20 (15.7%) 0.422 Dizziness 5 (3.4%) 14 (18.2%) 12 (9.4%) 0.422 Corvusion 25 (16.8%) 5 (22.7%) 20 (15.7%) 0.422	Frequency of hospitalization	2.1 ± 1.7	1.2±0.7	2.2±1.8	0.030	0.437 (0.207, 0.924)
Dut-patient history 87 (58.4%) 13 (59.1%) 74 (58.3%) 0.942 impatient history 143 (96.0%) 21 (95.5%) 122 (96.1%) 0.893 Antibiotics therapy 114 (76.5%) 19 (86.4%) 95 (74.8%) 0.247 Anti-B therapy 31 (20.8%) 3 (13.6%) 2 (22.0%) 0.375 Symptoms 2004 13 (89.0%) 2 (21.3%) 0.415 Grever 132 (88.6%) 19 (86.4%) 13 (89.0%) 0.227 Vomitting 72 (48.3%) 13 (59.1%) 59 (46.5%) 0.277 Grever 132 (14.8%) 8 (36.4%) 14 (11.0%) 0.041 Coma 22 (14.8%) 8 (36.4%) 14 (11.0%) 0.412 Convalsion 25 (16.8%) 5 (22.7%) 20 (12.7%) 0.270 Drowsiness 5 (3.4%) 1 (4.5%) 4 (3.1%) 0.412 Convalsion 25 (16.8%) 5 (22.7%) 20 (12.7%) 0.270 Drowsiness 5 (3.4%) 1 (4.5%) 4 (11.0%) 0.412 Optopulancitar coll (0.10/L)	Treatment delay (days)	40±61	43±43	40±64	0.807	
Inpatient history 143 (96.0%) 21 (95.5%) 122 (96.1%) 0.893 Antibiotics therapy 114 (76.5%) 19 (86.4%) 95 (74.8%) 0.247 Anti-Th therapy 31 (20.8%) 3 (13.6%) 28 (22.0%) 0.375 Symptoms	Self-treatment	20 (13.4%)	6 (27.3%)	14 (11.0%)	0.046	3.027 (1.017, 9.005)
Antibiotics therapy 114 (76.5%) 19 (86.4%) 95 (74.8%) 0.247 Anti-TB therapy 31 (20.8%) 3 (13.6%) 28 (22.0%) 0.375 Symptoms 20 (20.1%) 3 (13.6%) 27 (21.3%) 0.415 Cough 30 (20.1%) 3 (13.6%) 27 (21.3%) 0.415 Fever 132 (88.6%) 19 (86.4%) 113 (89.0%) 0.722 Vomitting 72 (48.3%) 13 (59.1%) 59 (46.5%) 0.277 Headache 77 (51.7%) 9 (40.9%) 68 (53.5%) 0.277 Coma 22 (14.8%) 8 (36.4%) 14 (11.0%) 0.004 4.612(1.645, 12.932) Drowsiness 14 (9.4%) 1 (4.5%) 13 (10.2%) 0.412 Convulsion 25 (16.8%) 5 (22.7%) 20 (15.7%) 0.422 Oriziness 5 (3.4%) 1 (4.2%) 12 (9.4%) 0.70 Carebrospinal fluid analysis Carebrospinal fluid analysis 76±25 76±24 76±25 0.649 Mononuclear cell (%) <t< td=""><td>Out-patient history</td><td>87 (58.4%)</td><td>13 (59.1%)</td><td>74 (58.3%)</td><td>0.942</td><td></td></t<>	Out-patient history	87 (58.4%)	13 (59.1%)	74 (58.3%)	0.942	
Anti-TB therapy 31 (20.8%) 3 (13.6%) 28 (22.0%) 0.375 Symptoms Cough 30 (20.1%) 3 (13.6%) 27 (21.3%) 0.415 Fever 132 (88.6%) 19 (86.4%) 113 (89.0%) 0.722 Vomitting 72 (48.3%) 13 (59.1%) 59 (46.5%) 0.277 Headache 77 (51.7%) 9 (40.9%) 68 (53.5%) 0.277 Coma 22 (14.8%) 8 (36.4%) 14 (11.0%) 0.004 4.612(1.645,12.932) Drowsiness 14 (9.4%) 1 (4.5%) 13 (10.2%) 0.412 Convulsion 25 (16.8%) 5 (22.7%) 20 (15.7%) 0.422 Obrexiness 5 (3.4%) 1 (4.5%) 13 (10.2%) 0.70 Symptoms related to cranial nerve involvement* 16 (10.7%) 4 (18.2%) 12 (9.4%) 0.70 Whie blood cell (10 ⁶ /L) 156.2 + 28.35 7.8 + 109.4 170.9 + 301.8 0.114 Mononuclear cell (%) 76 ± 25 76 ± 24 76 ± 25 0.649	Inpatient history	143 (96.0%)	21 (95.5%)	122 (96.1%)	0.893	
Symptoms Symptoms Symptoms Cough 30 (20.1%) 3 (13.6%) 27 (21.3%) 0.415 Fever 132 (88.6%) 19 (86.4%) 113 (89.0%) 0.722 Vomitting 72 (48.3%) 13 (59.1%) 59 (46.5%) 0.277 Headache 77 (51.7%) 9 (40.9%) 68 (53.5%) 0.277 Coma 22 (14.8%) 8 (36.4%) 14 (11.0%) 0.041 4.612(1.645, 12.932) Drowsiness 14 (9.4%) 1 (4.5%) 13 (10.2%) 0.412 Convulsion Convulsion 25 (16.8%) 5 (22.7%) 20 (15.7%) 0.422 Convulsion Dizziness 5 (3.4%) 1 (4.5%) 4 (3.1%) 0.739 Convulsion Symptoms related to cranial nerve involvement* 16 (10.7%) 4 (18.2%) 12 (9.4%) 0.270 Cerebrospinal fluid analysis 76±25 76±24 76±25 0.649 Polyonuclear cell (%) 25±25 25±24 24±25 0.947 Lactate (mmol/L) 15±11 20±14 14±10 0.616	Antibiotics therapy	114 (76.5%)	19 (86.4%)	95 (74.8%)	0.247	
Coup 30 (20.1%) 3 (13.6%) 27 (21.3%) 0.415 Fever 132 (88.6%) 19 (86.4%) 113 (89.0%) 0.722 Womitting 72 (48.3%) 13 (59.1%) 59 (46.5%) 0.277 Headache 77 (51.7%) 9 (40.9%) 68 (53.5%) 0.277 Coma 22 (14.8%) 8 (36.4%) 14 (11.0%) 0.004 4.612(1.645, 12.932) Drowsiness 14 (9.4%) 1 (4.5%) 13 (10.2%) 0.412 0.270 Convulsion 25 (16.8%) 5 (22.7%) 20 (15.7%) 0.422 0.270 Dizziness 5 (3.4%) 1 (4.8.2%) 12 (9.4%) 0.739 0.270 Symptoms related to cranial nerve involvement* 16 (10.7%) 4 (18.2%) 12 (9.4%) 0.270 Cerebrospinal fluid analysis Cerebrospinal fluid analysis 0.114 14 14 Mononuclear cell (%) 76±25 76±24 76±25 0.649 Polyonuclear cell (%) 25±25 25±24 24±25 0.947 Icateate (mmol/L) 15±11	Anti-TB therapy	31 (20.8%)	3 (13.6%)	28 (22.0%)	0.375	
Description Description <thdescription< th=""> <thdescription< th=""></thdescription<></thdescription<>	Symptoms					1
Vomitting 72 (48.3%) 13 (59.1%) 59 (46.5%) 0.277 Headache 77 (51.7%) 9 (40.9%) 68 (53.5%) 0.277 Coma 22 (14.8%) 8 (36.4%) 14 (11.0%) 0.004 4.612(1.645, 12.932) Drowsiness 14 (9.4%) 1 (4.5%) 13 (10.2%) 0.412 Convulsion 25 (16.8%) 5 (22.7%) 20 (15.7%) 0.422 Dizziness 5 (3.4%) 1 (4.5%) 4 (3.1%) 0.739 Symptoms related to cranial nerve involvement* 16 (10.7%) 4 (18.2%) 12 (9.4%) 0.270 Cerebrospinal fluid analysis 5 71.8±109.4 170.9±301.8 0.114 Mononuclear cell (%) 76±25 76±24 76±25 0.649 Polynouclear cell (%) 72±75 25±24 24±25 0.947 Lactate (mmol/L) 4.5±119 5.2±1.00 4.42±1.97 0.235 Total protein (g/L) 984±758 1412±1110 917±670 0.019 1.001 (1.000, 1.001) Adenosine deaminase (U/L)	Cough	30 (20.1%)	3 (13.6%)	27 (21.3%)	0.415	
Headache $77 (51.7\%)$ $9 (40.9\%)$ $68 (53.5\%)$ 0.277 Coma $22 (14.8\%)$ $8 (36.4\%)$ $14 (11.0\%)$ 0.004 $4.612 (1.645, 12.332)$ Drowsiness $14 (9.4\%)$ $1 (4.5\%)$ $13 (10.2\%)$ 0.412 Convulsion $25 (16.8\%)$ $5 (22.7\%)$ $20 (15.7\%)$ 0.422 Dizziness $5 (3.4\%)$ $1 (4.5\%)$ $4 (3.1\%)$ 0.739 Symptoms related to cranial nerve involvement* $16 (10.7\%)$ $4 (18.2\%)$ $12 (9.4\%)$ 0.270 Cerebrospinal fluid analysisWhite blood cell ($10^{0}/L$) 156.2 ± 283.5 71.8 ± 109.4 170.9 ± 301.8 0.114 Mononuclear cell (%) 76 ± 25 76 ± 24 76 ± 25 0.649 Polyonuclear cell (%) 76 ± 25 25 ± 24 24 ± 25 0.947 Catate (mmol/L) 4.56 ± 1.99 5.28 ± 2.00 4.42 ± 1.97 0.235 Total protein (g/L) 984 ± 758 1412 ± 1110 917 ± 670 0.019 $1.001 (1.000, 1.001)$ Adenosine deaminase (U/L) 15 ± 11 20 ± 14 14 ± 10 0.61 Lactate dehydrogenase (U/L) 55 ± 10.8 42 ± 4.4 5.7 ± 11.5 0.617 Lactate dehydrogenase (U/L) 69 ± 103 107 ± 113 63 ± 101 0.135 Lactate dehydrogenase (U/L) 65 ± 55 72 ± 77 40 ± 50 0.47 $1.007 (1.000, 1.014)$ Total bilirubin (mol/L) 0.15 ± 0.48 0.22 ± 0.46 0.14 ± 0.44 0.505 Lactate dehydrogenase (U/L) 61 ± 0.35 72 ± 7.7 40 ± 50 0.4	Fever	132 (88.6%)	19 (86.4%)	113 (89.0%)	0.722	
Coma22 (14.8%)8 (36.4%)14 (11.0%)0.0044.612(1.645, 12.932)Drowsiness14 (9.4%)1 (4.5%)13 (10.2%)0.412Convulsion25 (16.8%)5 (22.7%)20 (15.7%)0.422Dizziness5 (3.4%)1 (4.5%)4 (3.1%)0.739Symptoms related to cranial nerve involvement*16 (10.7%)4 (18.2%)12 (9.4%)0.270Cerebrospinal fluid analysisWhite blood cell (10%/L)156.2 ± 283.571.8 ± 109.4170.9 ± 301.80.114Mononuclear cell (%)76 ± 2576 ± 2476 ± 250.649Polyonuclear cell (%)25 ± 2525 ± 2424 ± 250.947Catcate (mmol/L)4.56 ± 1.995.28 ± 2.004.42 ± 1.970.235Total protein (g/L)984 ± 7581412 ± 1110917 ± 6700.0191.001 (1.000, 1.001)Aspartate aminotransferase (U/L)15 ± 1120 ± 1414 ± 100.061Total bilirubin (mmol/L)1.01 ± 2.571.21 ± 1.370.98 ± 2.710.739Adenosine deaminase (U/L)69 ± 103107 ± 11363 ± 1010.135Actate dehydrogenase (U/L)69 ± 103107 ± 11363 ± 1010.135Glucose (mmol/L)0.15 ± 0.440.22 ± 0.460.14 ± 0.440.505Glucose (mmol/L)0.15 ± 0.440.22 ± 0.460.14 ± 0.440.505Glucose (mmol/L)18.38 ± 13.5118.91 ± 17.2618.16 ± 12.230.0421.043 (1.001, 1.085)(gG (mg/L)80.63 ± 31.5280.24 ± 35.3880.79 ±	Vomitting	72 (48.3%)	13 (59.1%)	59 (46.5%)	0.277	
Drowsiness14 (9.4%)1 (4.5%)13 (10.2%)0.412Convulsion25 (16.8%)5 (22.7%)20 (15.7%)0.422Dizziness5 (3.4%)1 (4.5%)4 (3.1%)0.739Symptoms related to cranial nerve involvement*16 (10.7%)4 (18.2%)12 (9.4%)0.270Cerebrospinal fluid analysis16 (10.7%)4 (18.2%)12 (9.4%)0.270Cerebrospinal fluid analysis 76 ± 25 76 ± 24 76 ± 25 0.649Monouclear cell (%) 76 ± 25 76 ± 24 76 ± 25 0.649Polyonuclear cell (%) 25 ± 25 25 ± 24 24 ± 25 0.947Lactate (mmol/L) 4.56 ± 1.99 5.28 ± 2.00 4.42 ± 1.97 0.235Total protein (g/L) 984 ± 758 1412±1110 917 ± 670 0.0191.001 (1.000, 1.001)Aspartate aminotransferase (U/L) 15 ± 11 20 ± 14 14 ± 10 0.661Total bilirubin (mmol/L) 1.01 ± 2.57 1.21 ± 1.37 0.98 ± 2.71 0.739 Adenosine deaminase (U/L) 55 ± 10.8 4.2 ± 4.4 5.7 ± 11.5 0.617Lactate dehydrogenase (U/L) 69 ± 103 107 ± 113 63 ± 101 0.135a-hydroxybutyrate dehydrogenase (U/L) 45 ± 55 72 ± 77 40 ± 50 0.047 $1.007 (1.000, 1.014)$ Total cholesterol (mmol/L) 0.15 ± 0.44 0.22 ± 0.46 0.14 ± 0.44 0.505 [Gucose (mmol/L) 0.329 [gA (mg/L) 2.01 ± 1.06 1.79 ± 0.78 2.05 ± 1.10 0.329 [Gmarcal (mmol/L) 10.33 ± 1.52 80.24 ± 3.538 80.79 ± 3.83	Headache	77 (51.7%)	9 (40.9%)	68 (53.5%)	0.277	
Convulsion $25 (16.8\%)$ $5 (22.7\%)$ $20 (15.7\%)$ 0.422 Dizziness $5 (3.4\%)$ $1 (4.5\%)$ $4 (3.1\%)$ 0.739 Symptoms related to cranial nerve involvement* $16 (10.7\%)$ $4 (3.1\%)$ 0.270 Ccerebrospinal fluid analysisWhite blood cell $(10^{\circ}/L)$ 156.2 ± 283.5 71.8 ± 109.4 170.9 ± 301.8 0.114 Mononuclear cell $(\%)$ 76 ± 25 76 ± 24 76 ± 25 0.649 Polyonuclear cell $(\%)$ 25 ± 25 25 ± 24 24 ± 25 0.947 Lactate (mmol/L) 4.56 ± 1.99 5.28 ± 2.00 4.42 ± 1.97 0.235 Total protein (g/L) 98 ± 758 1412 ± 1110 917 ± 670 0.019 $1.001 (1.000, 1.001)$ Adenosine deaminase (U/L) 5.5 ± 10.8 4.2 ± 4.4 5.7 ± 11.5 0.617 Cattate dehydrogenase (U/L) 69 ± 103 107 ± 113 63 ± 101 0.135 Adenosine deaminase (U/L) 69 ± 103 107 ± 113 63 ± 101 0.135 Cattate dehydrogenase (U/L) 45 ± 55 72 ± 77 40 ± 50 0.442 $1.007 (1.000, 1.014)$ Total cholesterol (mmol/L) 0.15 ± 0.44 0.22 ± 0.46 0.14 ± 0.44 0.505 Cattate dehydrogenase (U/L) 41 ± 0.6 0.239 Cattate dehydrogenase (U/L) 0.15 ± 0.44 0.22 ± 1.10 0.329 Cattate dehydrogenase (U/L) 0.15 ± 0.44 0.22 ± 1.16 <	Coma	22 (14.8%)	8 (36.4%)	14 (11.0%)	0.004	4.612(1.645, 12.932)
Dizziness 5 (3.4%) 1 (4.5%) 4 (3.1%) 0.739 Symptoms related to cranial nerve involvement* 16 (10.7%) 4 (18.2%) 12 (9.4%) 0.270 Ccrebrospinal fluid analysis U 156.2±283.5 71.8±109.4 170.9±301.8 0.114 Mononuclear cell (%) 76±25 76±24 76±25 0.649 Polyonuclear cell (%) 25±25 25±24 24±25 0.947 Lactate (mmol/L) 4.56±1.99 5.28±2.00 4.42±1.97 0.235 Total protein (g/L) 984±758 1412±1110 917±670 0.019 1.001 (1.000, 1.001) Aspartate aminotransferase (U/L) 15±11 20±14 14±10 0.061 Total bilirubin (mmol/L) 1.01±2.57 1.21±1.37 0.98±2.71 0.739 Adenosine deaminase (U/L) 69±103 107±113 63±101 0.135 Cattate dehydrogenase (U/L) 45±55 72±77 40±50 0.047 1.007 (1.000, 1.014) Total cholesterol (mmol/L) 0.15±0.44 0.22±0.46 0.14±0.44 0.505 1140±0.43 (1.001, 1	Drowsiness	14 (9.4%)	1 (4.5%)	13 (10.2%)	0.412	
Symptoms related to cranial nerve involvement* 16 (10.7%) 4 (18.2%) 12 (9.4%) 0.270 Cerebrospinal fluid analysis 156.2±283.5 71.8±109.4 170.9±301.8 0.114 Mononuclear cell (%) 76±25 76±24 76±25 0.649 Polyonuclear cell (%) 25±25 25±24 24±25 0.947 Lactate (mmol/L) 4.56±1.99 5.28±2.00 4.42±1.97 0.235 Fotal protein (g/L) 984±758 1412±1110 917±670 0.019 1.001 (1.000, 1.001) Aspartate aminotransferase (U/L) 15±11 20±14 14±10 0.061 Total bilirubin (mmol/L) 1.01±2.57 1.21±1.37 0.98±2.71 0.739 Adenosine deaminase (U/L) 5.5±10.8 4.2±4.4 5.7±11.5 0.617 Lactate dehydrogenase (U/L) 69±103 107±113 63±101 0.135 a-hydroxybutyrate dehydrogenase (U/L) 45±55 72±77 40±50 0.047 1.007 (1.000, 1.014) Total cholesterol (mmol/L) 0.15±0.44 0.22±0.46 0.14±0.44 0.505 Glucose (mm	Convulsion	25 (16.8%)	5 (22.7%)	20 (15.7%)	0.422	
Crebrospinal fluid analysis 156.2±283.5 71.8±109.4 170.9±301.8 0.114 Mononuclear cell (%) 76±25 76±24 76±25 0.649 Polyonuclear cell (%) 25±25 25±24 24±25 0.947 Lactate (mmol/L) 4.56±1.99 5.28±2.00 4.42±1.97 0.235 Total protein (g/L) 984±758 1412±1110 917±670 0.019 1.001 (1.000, 1.001) Aspartate aminotransferase (U/L) 15±11 20±14 14±10 0.061 Fotal bilirubin (mmol/L) 1.01±2.57 1.21±1.37 0.98±2.71 0.739 Adenosine deaminase (U/L) 5.5±10.8 4.2±4.4 5.7±11.5 0.617 Lactate dehydrogenase (U/L) 69±103 107±113 63±101 0.135 x-hydroxybutyrate dehydrogenase (U/L) 45±55 72±77 40±50 0.047 1.007 (1.000, 1.014) Total cholesterol (mmol/L) 0.15±0.44 0.22±0.46 0.14±0.44 0.505 Glucose (mmol/L) 1.03838±13.51 18.91±17.26 18.16±12.23 0.042 1.043 (1.001, 1.085)	Dizziness	5 (3.4%)	1 (4.5%)	4 (3.1%)	0.739	
White blood cell (10 ⁶ /L) 156.2±283.5 71.8±109.4 170.9±301.8 0.114 Mononuclear cell (%) 76±25 76±24 76±25 0.649 Polyonuclear cell (%) 25±25 25±24 24±25 0.947 Lactate (mmol/L) 4.56±1.99 5.28±2.00 4.42±1.97 0.235 Total protein (g/L) 984±758 1412±1110 917±670 0.019 1.001 (1.000, 1.001) Aspartate aminotransferase (U/L) 15±11 20±14 14±10 0.061 Total bilirubin (mmol/L) 1.01±2.57 1.21±1.37 0.98±2.71 0.739 Adenosine deaminase (U/L) 5.5±10.8 4.2±4.4 5.7±11.5 0.617 Lactate dehydrogenase (U/L) 69±103 107±113 63±101 0.135 Chalcholesterol (mmol/L) 0.15±0.44 0.22±0.46 0.14±0.44 0.505 Glucose (mmol/L) 2.01±1.06 1.79±0.78 2.05±1.10 0.329 IgA (mg/L) 18.38±13.51 18.91±17.26 18.16±12.23 0.042 1.043 (1.001, 1.085) IgG (mg/L) 80.63±31	Symptoms related to cranial nerve involvement*	16 (10.7%)	4 (18.2%)	12 (9.4%)	0.270	
Mononuclear cell (%) 76±25 76±24 76±25 0.649 Polyonuclear cell (%) 25±25 25±24 24±25 0.947 Lactate (mmol/L) 4.56±1.99 5.28±2.00 4.42±1.97 0.235 Total protein (g/L) 984±758 1412±1110 917±670 0.019 1.001 (1.000, 1.001) Aspartate aminotransferase (U/L) 15±11 20±14 14±10 0.061 1.011 (1.000, 1.001) Adenosine deaminase (U/L) 1.01±2.57 1.21±1.37 0.98±2.71 0.739 1.011 (1.000, 1.001) Adenosine deaminase (U/L) 69±103 107±113 63±101 0.135 1.007 (1.000, 1.014) Total cholesterol (mmol/L) 0.15±0.44 0.22±0.46 0.14±0.44 0.505 1.007 (1.000, 1.014) Total cholesterol (mmol/L) 0.15±0.44 0.22±0.46 0.14±0.44 0.505 1.007 (1.000, 1.014) Glucose (mmol/L) 0.15±0.44 0.22±0.46 0.14±0.44 0.505 1.003 (1.001, 1.085) IgA (mg/L) 80.63±31.52 80.24±35.38 80.79±30.83 0.966 1.043 (1.001, 1.085) <	Cerebrospinal fluid analysis	1	I.	1	1	1
Number Numer Numer Numer <td>White blood cell (10⁶/L)</td> <td>156.2±283.5</td> <td>71.8 ± 109.4</td> <td>170.9±301.8</td> <td>0.114</td> <td></td>	White blood cell (10 ⁶ /L)	156.2±283.5	71.8 ± 109.4	170.9±301.8	0.114	
Lactate (mmol/L) 4.56±1.99 5.28±2.00 4.42±1.97 0.235 Total protein (g/L) 984±758 1412±1110 917±670 0.019 1.001 (1.000, 1.001) Aspartate aminotransferase (U/L) 15±11 20±14 14±10 0.061 Total bilirubin (mmol/L) 1.01±2.57 1.21±1.37 0.98±2.71 0.739 Adenosine deaminase (U/L) 5.5±10.8 4.2±4.4 5.7±11.5 0.617 Lactate dehydrogenase (U/L) 69±103 107±113 63±101 0.135 x-hydroxybutyrate dehydrogenase (U/L) 45±55 72±77 40±50 0.047 1.007 (1.000, 1.014) Total cholesterol (mmol/L) 0.15±0.44 0.22±0.46 0.14±0.44 0.505 0.047 1.007 (1.000, 1.014) Total cholesterol (mmol/L) 0.15±0.44 0.22±0.46 0.14±0.44 0.505 0.042 1.043 (1.001, 1.085) IgA (mg/L) 18.38±13.51 18.91±17.26 18.16±12.23 0.042 1.043 (1.001, 1.085) IgG (mg/L) 80.63±31.52 80.24±35.38 80.79±30.83 0.966 1.043 (1.001, 1.085) IgM (mg/L) 4.28±1.19 4.18±1.29 4.32±1.17	Mononuclear cell (%)	76±25	76±24	76±25	0.649	
Total protein (g/L) 984±758 1412±1110 917±670 0.019 1.001 (1.000, 1.001) Aspartate aminotransferase (U/L) 15±11 20±14 14±10 0.061 Total bilirubin (mmol/L) 1.01±2.57 1.21±1.37 0.98±2.71 0.739 Adenosine deaminase (U/L) 5.5±10.8 4.2±4.4 5.7±11.5 0.617 Lactate dehydrogenase (U/L) 69±103 107±113 63±101 0.135 x-hydroxybutyrate dehydrogenase (U/L) 45±55 72±77 40±50 0.047 1.007 (1.000, 1.014) Total cholesterol (mmol/L) 0.15±0.44 0.22±0.46 0.14±0.44 0.505 Glucose (mmol/L) 2.01±1.06 1.79±0.78 2.05±1.10 0.329 IgA (mg/L) 80.63±31.52 80.24±35.38 80.79±30.83 0.966 IgM (mg/L) 4.28±1.19 4.18±1.29 4.32±1.17 0.773 Chloride (mmol/L) 113.3±7.2 108.8±5.5 114.0±7.2 0.231	Polyonuclear cell (%)	25±25	25±24	24±25	0.947	
Asparate aminotransferase (U/L) 15±11 20±14 14±10 0.061 Fotal bilirubin (mmol/L) 1.01±2.57 1.21±1.37 0.98±2.71 0.739 Adenosine deaminase (U/L) 5.5±10.8 4.2±4.4 5.7±11.5 0.617 Lactate dehydrogenase (U/L) 69±103 107±113 63±101 0.135 x-hydroxybutyrate dehydrogenase (U/L) 45±55 72±77 40±50 0.047 1.007 (1.000, 1.014) Total cholesterol (mmol/L) 0.15±0.44 0.22±0.46 0.14±0.44 0.505 0.042 1.043 (1.001, 1.085) Glucose (mmol/L) 2.01±1.06 1.79±0.78 2.05±1.10 0.329 0.42 1.043 (1.001, 1.085) IgG (mg/L) 80.63±31.52 80.24±35.38 80.79±30.83 0.966 0.966 IgM (mg/L) 4.28±1.19 4.18±1.29 4.32±1.17 0.773 0.773 Chloride (mmol/L) 113.3±7.2 108.8±5.5 114.0±7.2 0.231 0.231	Lactate (mmol/L)	4.56±1.99	5.28 ± 2.00	4.42 ± 1.97	0.235	
Total bilirubin (mmol/L) 1.01±2.57 1.21±1.37 0.98±2.71 0.739 Adenosine deaminase (U/L) 5.5±10.8 4.2±4.4 5.7±11.5 0.617 Lactate dehydrogenase (U/L) 69±103 107±113 63±101 0.135 x-hydroxybutyrate dehydrogenase (U/L) 45±55 72±77 40±50 0.047 1.007 (1.000, 1.014) Total cholesterol (mmol/L) 0.15±0.44 0.22±0.46 0.14±0.44 0.505 6 Glucose (mmol/L) 2.01±1.06 1.79±0.78 2.05±1.10 0.329 1.043 (1.001, 1.085) igG (mg/L) 80.63±31.52 80.24±35.38 80.79±30.83 0.966 1.043 (1.001, 1.085) igM (mg/L) 4.28±1.19 4.18±1.29 4.32±1.17 0.773 1.043 (1.001, 1.085) Chloride (mmol/L) 113.3±7.2 108.8±5.5 114.0±7.2 0.231 1.043 (1.001, 1.085)	Total protein (g/L)	984±758	1412±1110	917±670	0.019	1.001 (1.000, 1.001)
Adenosine deaminase (U/L) 5.5±10.8 4.2±4.4 5.7±11.5 0.617 Lactate dehydrogenase (U/L) 69±103 107±113 63±101 0.135 x-hydroxybutyrate dehydrogenase (U/L) 45±55 72±77 40±50 0.047 1.007 (1.000, 1.014) Total cholesterol (mmol/L) 0.15±0.44 0.22±0.46 0.14±0.44 0.505 6 Glucose (mmol/L) 2.01±1.06 1.79±0.78 2.05±1.10 0.329 1.043 (1.001, 1.085) IgA (mg/L) 18.38±13.51 18.91±17.26 18.16±12.23 0.042 1.043 (1.001, 1.085) IgM (mg/L) 4.28±1.19 4.18±1.29 4.32±1.17 0.773 6 Chloride (mmol/L) 113.3±7.2 108.8±5.5 114.0±7.2 0.231 1	Aspartate aminotransferase (U/L)	15±11	20±14	14±10	0.061	
Lactate dehydrogenase (U/L) 69±103 107±113 63±101 0.135 x-hydroxybutyrate dehydrogenase (U/L) 45±55 72±77 40±50 0.047 1.007 (1.000, 1.014) Total cholesterol (mmol/L) 0.15±0.44 0.22±0.46 0.14±0.44 0.505 Glucose (mmol/L) 2.01±1.06 1.79±0.78 2.05±1.10 0.329 IgA (mg/L) 18.38±13.51 18.91±17.26 18.16±12.23 0.042 1.043 (1.001, 1.085) IgG (mg/L) 80.63±31.52 80.24±35.38 80.79±30.83 0.966 1.097 (1.000, 1.014) Chloride (mmol/L) 113.3±7.2 108.8±5.5 114.0±7.2 0.231	Total bilirubin (mmol/L)	1.01±2.57	1.21 ± 1.37	0.98±2.71	0.739	
a-hydroxybutyrate dehydrogenase (U/L) 45±55 72±77 40±50 0.047 1.007 (1.000, 1.014) Total cholesterol (mmol/L) 0.15±0.44 0.22±0.46 0.14±0.44 0.505 Glucose (mmol/L) 2.01±1.06 1.79±0.78 2.05±1.10 0.329 IgA (mg/L) 18.38±13.51 18.91±17.26 18.16±12.23 0.042 1.043 (1.001, 1.085) IgG (mg/L) 80.63±31.52 80.24±35.38 80.79±30.83 0.966 IgM (mg/L) 4.28±1.19 4.18±1.29 4.32±1.17 0.773 Chloride (mmol/L) 113.3±7.2 108.8±5.5 114.0±7.2 0.231	Adenosine deaminase (U/L)	5.5 ± 10.8	4.2 ± 4.4	5.7±11.5	0.617	
Total cholesterol (mmol/L) 0.15±0.44 0.22±0.46 0.14±0.44 0.505 Glucose (mmol/L) 2.01±1.06 1.79±0.78 2.05±1.10 0.329 IgA (mg/L) 18.38±13.51 18.91±17.26 18.16±12.23 0.042 1.043 (1.001, 1.085) IgG (mg/L) 80.63±31.52 80.24±35.38 80.79±30.83 0.966 IgM (mg/L) 4.28±1.19 4.18±1.29 4.32±1.17 0.773 Chloride (mmol/L) 113.3±7.2 108.8±5.5 114.0±7.2 0.231	Lactate dehydrogenase (U/L)	69±103	107±113	63±101	0.135	
Glucose (mmol/L) 2.01±1.06 1.79±0.78 2.05±1.10 0.329 IgA (mg/L) 18.38±13.51 18.91±17.26 18.16±12.23 0.042 1.043 (1.001, 1.085) IgG (mg/L) 80.63±31.52 80.24±35.38 80.79±30.83 0.966 IgM (mg/L) 4.28±1.19 4.18±1.29 4.32±1.17 0.773 Chloride (mmol/L) 113.3±7.2 108.8±5.5 114.0±7.2 0.231	α-hydroxybutyrate dehydrogenase (U/L)	45±55	72±77	40 ± 50	0.047	1.007 (1.000, 1.014)
igA (mg/L) 18.38±13.51 18.91±17.26 18.16±12.23 0.042 1.043 (1.001, 1.085) igG (mg/L) 80.63±31.52 80.24±35.38 80.79±30.83 0.966 igM (mg/L) 4.28±1.19 4.18±1.29 4.32±1.17 0.773 Chloride (mmol/L) 113.3±7.2 108.8±5.5 114.0±7.2 0.231	Total cholesterol (mmol/L)	0.15 ± 0.44	0.22 ± 0.46	0.14 ± 0.44	0.505	
Image: Second	Glucose (mmol/L)	2.01 ± 1.06	1.79±0.78	2.05 ± 1.10	0.329	
IgM (mg/L) 4.28±1.19 4.18±1.29 4.32±1.17 0.773 Chloride (mmol/L) 113.3±7.2 108.8±5.5 114.0±7.2 0.231	IgA (mg/L)	18.38±13.51	18.91±17.26	18.16±12.23	0.042	1.043 (1.001, 1.085)
Chloride (mmol/L) 113.3±7.2 108.8±5.5 114.0±7.2 0.231	IgG (mg/L)	80.63±31.52	80.24±35.38	80.79±30.83	0.966	
	IgM (mg/L)	4.28±1.19	4.18±1.29	4.32 ± 1.17	0.773	
	Chloride (mmol/L)		108.8 ± 5.5			
	Microbiological assays** (+)	30 (20.1%)	5 (22.7%)	25 (19.7%)	0.835	

Table 1. Univariate analysis of the demographic data associated with poor outcome in childhood tuberculous meningitis. *TB*, tuberculosis, *OR*, odds ratio, *CI* confidence interval. *Symptoms related to cranial nerve involvement include motor abnormalitie, speech difficulties, swallowing difficulties, and visual loss. **Microbiological assays include CSF AFB smear, CSF PCR, CSF Xpert, and CSF culture ("+" means at least 1 assay (+)).

	Adjusted (age and sex) OR	P value
Coma	6.425 (1.743, 23.676)	0.005
CSF protein (>1188.3 mg/L)	4.680 (1.469, 14.902)	0.009

 Table 2. Age- and sex-adjusted OR for risk factors associated with poor outcome in childhood tuberculous meningitis. *TBM* tuberculous meningitis, *OR* odds ratio, *CI* confidence interval.

significant difference was observed in treatment delay between the poor and good outcome groups. Nevertheless, in the study, the treatment delay remains strongly suspected. Frequency of hospitalization was found to be associated with poor outcome in univariate analysis. On the one hand, the frequency of hospitalization may be associated with a prolonged period seeking an appropriate treatment. On the other hand, transfers between hospitals are more prone to support that these individuals have a more serious situation due to a delayed diagnosis or inappropriate treatment. Additionally, self-treatment also appeared to play a role in the treatment delay. However, this fact was not included in the final regression model.

Not surprisingly, coma is identified as a risk factor of poor outcome in our study. This may be explained that poor outcomes in TBM were largely confined to cases presenting in an advanced stage¹⁶. Similar observations were reported in several studies^{13,17,18}. In our study, 22 (14.8%) of them had coma on arrival. In Romania, coma was noted in a similar proportion¹⁹. However, in low TB burden countries, this appears to be rare²⁰. Although Glasgow coma scale has been introduced to evaluate the severity and predict the outcome of TBM²¹ and a low Glasgow coma scale (GCS) score on admission was associated with a poor prognosis, the accurate criteria (score cut-off) for this is not well characterized. For example, GCS (score: 3–8) is thought as an independent predictor of poor outcome in TBM patients²²; the scale with ≤ 10 has a poor outcome²³. In contrast, compared with Glasgow coma scale, coma as a symptom may be easy to use in the management of childhood TBM. Besides, if only death is defined as poor outcome, coma remains to be a risk factor for poor outcome of childhood TBM (data not shown).

Usually, a high level of CSF protein indicates disruption of the blood–brain barrier and the subarachnoid blockage of the CNS circulation in central nervous system involvement of tuberculosis, especially in tuberculous meningitis^{24–26}. Besides, an elevated level of CSF protein is also known as an enhanced immunological reaction²⁷. In the study, high level of CSF protein was identified as another risk factor for the poor outcome in children with TBM. As known, CSF examination of TBM patients showed low glucose, high protein, and pleocytosis^{17,28}, and these CSF findings also served as criteria for the diagnosis of TBM. Previously, the association between CSF findings and outcome has been confirmed in adulthood TBM. For example, Hosoğlu et al. reported that high level of CSF protein is associated with poor outcome of childhood TBM. Besides this, several interesting findings about CSF protein were yielded recently. Such as faster normalization of CSF parameters (such as glucose, high protein, and pleocytosis) was associated with better outcome²⁸; an increased level of CSF protein may cause more formation of basal exudates in patients with TBM, leading to cranial nerve involvement³⁰.

The study has several limitations that should be taken into account. First, our study has a retrospective nature and a long inclusion period, during which diagnostic assays and treatment may have improved. Second, due to the observational and exploratory nature, the results may not be generalized to other settings. Third, due to the limited information collected from medical records and small sample size, our study did not address the relationship between GCS and outcome. Fourth, transfer to a higher-level hospital is defined as a poor outcome of childhood TBM. However, it does not mean that patient required transfer would experience death. Hence, our results should be interpreted with care. In a word, further analysis is needed to address the above mentioned questions and validate our findings in a large-scale prospective study.

Conclusions

During the last decade, childhood TBM remains to have a high mortality rate in China. The study identified several risk factors of poor outcome, such as high level of CSF protein and coma. Childhood TBM remains a severe problem to the public health and more attention are required to initiate anti-TB therapy timely.

Received: 27 November 2020; Accepted: 19 March 2021 Published online: 21 April 2021

References

- 1. Dong, Y. *et al.* Infectious diseases in children and adolescents in China: analysis of national surveillance data from 2008 to 2017. *BMJ* **369**, m1043 (2020).
- 2. Yang, R. *et al.* The epidemiology of pulmonary tuberculosis in children in Mainland China, 2009–2015. *Arch. Dis. Child.* **105**, 319–325 (2020).
- 3. Bang, N. D. *et al.* Clinical presentations, diagnosis, mortality and prognostic markers of tuberculous meningitis in Vietnamese children: a prospective descriptive study. *BMC Infect. Dis.* **16**, 573 (2016).
- 4. Dhawan, S. R. *et al.* Predictors of neurological outcome of tuberculous meningitis in childhood: a prospective cohort study from a developing country. *J. Child. Neurol.* **31**, 1622–1627 (2016).
- Israni, A. V. et al. Tubercular meningitis in children: clinical, pathological, and radiological profile and factors associated with mortality. J. Neurosci. Rural Pract. 7, 400–404 (2016).
- Wang, M. S., Wang, J. L. & Liu, X. J. Epidemiological trends in the form of childhood tuberculosis in a referral tuberculosis hospital in Shandong, China. *Biomed. Res. Int.* 2020, 6142567 (2020).

- 7. Boyles, T. H., Lynen, L. & Seddon, J. A. Tuberculous meningitis international research, C. Decision-making in the diagnosis of tuberculous meningitis. *Wellcome Open Res.* **5**, 11 (2020).
- Agarwal, S. et al. Comparative evaluation of IS6110 and protein antigen b PCR in cerebrospinal fluid for rapid diagnosis of tuberculous meningitis in children. J. Med. Microbiol. 69, 979–985 (2020).
- Jyothy, A., Ratageri, V. H., Illalu, S., Fattepur, S. R. & Wari, P. K. The Utility of CSF Xpert MTB/RIF in diagnosis of tubercular meningitis in children. Indian J. Pediatr. 86, 1089–1093 (2019).
- Wang, S. et al. The feasibility of metagenomic next-generation sequencing to identify pathogens causing tuberculous meningitis in cerebrospinal fluid. Front. Microbiol. 10, 1993 (2019).
- 11. Marais, S. et al. Tuberculous meningitis: a uniform case definition for use in clinical research. Lancet Infect. Dis. 10, 803–812 (2010).
- 12. Zhang, W., Han, C., Wang, M. S. & He, Y. Characteristics and factors associated with treatment delay in pleural tuberculosis. *QIM* 111, 779–783 (2018).
- 13. Hosoglu, S. et al. Predictors of outcome in patients with tuberculous meningitis. Int. J. Tuberc. Lung Dis. 6, 64-70 (2002).
- 14. Verdon, R., Chevret, S., Laissy, J. P. & Wolff, M. Tuberculous meningitis in adults: review of 48 cases. *Clin. Infect. Dis.* 22, 982–988 (1996).
- Sheu, J. J., Yuan, R. Y. & Yang, C. C. Predictors for outcome and treatment delay in patients with tuberculous meningitis. Am. J. Med. Sci. 338, 134–139 (2009).
- 16. Kent, S. J., Crowe, S. M., Yung, A., Lucas, C. R. & Mijch, A. M. Tuberculous meningitis: a 30-year review. Clin. Infect. Dis. 17, 987–994 (1993).
- Raberahona, M., Rakotoarivelo, R. A., Razafinambinintsoa, T., Andrianasolo, R. L. & Randria, M. J. Clinical features and outcome in adult cases of tuberculous meningitis in tertiary care hospital in Antananarivo, Madagascar. *Biomed. Res. Int.* 2017, 9316589 (2017).
- Yasar, K. K., Pehlivanoglu, F. & Sengoz, G. Predictors of mortality in tuberculous meningitis: a multivariate analysis of 160 cases. Int. J. Tuberc. Lung Dis. 14, 1330–1335 (2010).
- 19. Miftode, E. G. *et al.* Tuberculous meningitis in children and adults: a 10-year retrospective comparative analysis. *PLoS ONE* **10**, e0133477 (2015).
- 20. Christensen, A. S., Andersen, A. B., Thomsen, V. O., Andersen, P. H. & Johansen, I. S. Tuberculous meningitis in Denmark: a review of 50 cases. *BMC Infect. Dis.* 11, 47 (2011).
- 21. Gunes, A. *et al.* Clinical, radiological and laboratory findings in 185 children with tuberculous meningitis at a single centre and relationship with the stage of the disease. *Ital. J. Pediatr.* **41**, 75 (2015).
- 22. Mo, X., Xu, X., Ren, Z., Guan, J. & Peng, J. Patients with tuberculous meningitis and hepatitis B co-infection have increased risk for antituberculosis drug-induced liver injury and poor outcomes. *Infect. Dis. (Lond.)* **52**, 793–800 (2020).
- Jaipuriar, R. S. *et al.* Early mortality among immunocompetent patients of tuberculous meningitis: a prospective study. *Am. J. Trop. Med. Hyg.* 101, 357–361 (2019).
- Chaudhuri, A. & Behan, P. O. The clinical spectrum, diagnosis, pathogenesis and treatment of Hashimoto's encephalopathy (recurrent acute disseminated encephalomyelitis). Curr. Med. Chem. 10, 1945–1953 (2003).
- Haddad, N., McMinn, B. & Hartley, L. Headache meets neurology and psychiatry: a framework for diagnosis. Arch. Dis. Child. Educ. Pract. Ed. 101, 200–205 (2016).
- 26. van der Flier, M. *et al.* Vascular endothelial growth factor and blood-brain barrier disruption in tuberculous meningitis. *Pediatr. Infect. Dis. J.* **23**, 608–613 (2004).
- 27. Griffiths, M. J., McGill, F. & Solomon, T. Management of acute meningitis. Clin. Med. (Lond.) 18, 164-169 (2018).
- 28. Faella, F. S. *et al.* Factors influencing the presentation and outcome of tuberculous meningitis in childhood. *In Vivo* **20**, 187–191 (2006).
- Hosoglu, S., Ayaz, C., Geyik, M. F., Kokoglu, O. F. & Ceviz, A. Tuberculous meningitis in adults: an eleven-year review. Int. J. Tuberc. Lung Dis. 2, 553–557 (1998).
- Sharma, P., Garg, R. K., Verma, R., Singh, M. K. & Shukla, R. Incidence, predictors and prognostic value of cranial nerve involvement in patients with tuberculous meningitis: a retrospective evaluation. *Eur. J. Intern. Med.* 22, 289–295 (2011).

Author contributions

M.S.W and X.J.L designed the study. M.S.W collected and analyzed the data. M.S.W wrote the paper. M.Z revised the manuscript. All authors read and approved the final manuscript.

Competing interests

The authors declare no competing interests.

Additional information

Supplementary Information The online version contains supplementary material available at https://doi.org/ 10.1038/s41598-021-87082-5.

Correspondence and requests for materials should be addressed to X.-J.L.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021